EMA Authorised: Poteligeo (mogamulizumab) — Kyowa Kirin Holdings B.V.

View source ↗

Summary

The EMA authorised Poteligeo (mogamulizumab) for Sezary Syndrome and Mycosis Fungoides. The designation includes orphan medicine status and the decision date is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mycosis Fungoides
• Sezary Syndrome

Drugs mentioned

• Poteligeo (mogamulizumab)

Snippet

Status: Authorised. Therapeutic area: Sezary Syndrome;Mycosis Fungoides. MAH: Kyowa Kirin Holdings B.V.. Decision date: 08/04/2026. Orphan medicine